Theravance Biopharma Return on Equity

Theravance Biopharma (TBPH) currently reports a ROE of 18.57%. That is below the Healthcare sector average of 22.01%. Use the charts on this page to explore Theravance Biopharma's ROE history and peer comparisons.

Theravance Biopharma's ROE of 18.57% is lower than the Healthcare sector average of 22.01%. That is roughly 15.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Theravance Biopharma's current 18.57% should be judged against Healthcare norms (sector average: 22.01%) and against TBPH's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 18.57%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.01%. From there, open related valuation or income-statement pages for Theravance Biopharma, and consider following TBPH for alerts when major investors trade the stock.

Theravance Biopharma is classified in the Healthcare sector. On ROE, it currently shows 18.57% versus a sector average near 22.01%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TBPH with unrelated industries.